Project Grant R01HL173767
Award Date
9/15/24
Completion Date
5/31/28
Dollars Obligated
$1.4M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $420,600 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Colorado-Denver. The grant's objective is to design elastic hydrogel microparticles as a platform to measure key elements of platelet function, including adhesion, activation, aggregation, and contraction. This innovative "lab-on-a-particle" approach aims to improve the reliability and reproducibility of platelet function...
The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, awarded a $1,249,317 Project Grant to Sanaheal Inc. for the development and validation of a "Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding." The objective is to optimize and validate this hemostatic paste to meet FDA regulatory requirements in preparation for a future pivotal clinical trial and commercialization....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,250,837 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a gene editing approach using lipid nanoparticles (LNPs) and CRISPR/Cas9 tools to permanently correct the mutated Factor VIII (FVIII) gene and restore FVIII expression for the treatment of hemophilia A. The project aims to enhance LSEC-targeting of LNPs and...
This Project Grant award of $1,276,908 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research, will support advanced research by Bloodworks, a non-profit organization based in Seattle, Washington. The research aims to increase understanding of the mechanisms of disease in von Willebrand disease and sickle cell disease, which both involve the von Willebrand factor. Key focus areas include investigating the impact of VWF cleavage fragments...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $234,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to engineer and test "hemostatic red blood cells" (T-RBCs) for the treatment of acute non-compressible hemorrhage. The key objectives are to: 1) engineer T-RBCs that bind to collagen and fibrin to enhance clot formation and stability, 2) perform in vitro testing of the T-RBCs' hemostatic properties, and 3)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $764,817 to the University of North Carolina at Chapel Hill to conduct research on the mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia (APL). The study aims to determine the individual contributions of the podoplanin-CLEC-2 pathway, the S100/Annexin A2/tissue plasminogen activator and the urokinase-type plasminogen...
This Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of low-density lipoprotein (LDL) in hemostasis and its potential impact on hemophilia A, a hereditary bleeding disorder. The primary objectives are to: 1) Test the hypothesis that LDL associates with Factor VIII-von Willebrand Factor and improves hemostasis; 2) Evaluate if LDL extends Factor VIII half-life with slower clearance; and 3)...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $2,363,224 to The Washington University to conduct a comprehensive research program on von Willebrand factor and von Willebrand disease. The 5-year project, which began on May 15, 2025, aims to address key gaps in the genetic, molecular, and biological understanding of von Willebrand factor and its role in von Willebrand disease. The program consists of 4 research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,559,542 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Medical College of Wisconsin, Inc. to study the cardiometabolic impacts of gender-affirming hormone therapy (GAHT) in transmasculine young adults. The project aims to determine the effects of GAHT on vascular endothelial function, cardiometabolic biomarkers, and sex hormone receptor expression in this population, compared to cisgender...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...